Hyeong-Min Lee

Jul 8, 2024 | nature.com | Hanna Vihma |Audrey Smith |Rachel Gilmore |Justin Cotney |Jon Collins |Hyeong-Min Lee | +2 more

AbstractDeletion of the maternal UBE3A allele causes Angelman syndrome (AS); because paternal UBE3A is epigenetically silenced by a long non-coding antisense (UBE3A-ATS) in neurons, this nearly eliminates UBE3A protein in the brain. Reactivating paternal UBE3A holds promise for treating AS. We previously showed topoisomerase inhibitors can reactivate paternal UBE3A, but their therapeutic challenges prompted our search for small molecule unsilencers with a different mechanism of action.

Nov 12, 2023 | nature.com | Hyeong-Min Lee |Min Pan |Duane Currier |Richard H. Chapple |Xueying Liu |Jacob Steele | +6 more

AbstractCombination chemotherapy is crucial for successfully treating cancer. However, the enormous number of possible drug combinations means discovering safe and effective combinations remains a significant challenge. To improve this process, we conduct large-scale targeted CRISPR knockout screens in drug-treated cells, creating a genetic map of druggable genes that sensitize cells to commonly used chemotherapeutics.

Nov 9, 2023 | mdpi.com | Yuna Kim |Hyeong-Min Lee

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.